Sectors
CTKB
Cytek Biosciences, Inc.
4.78
2 x 3.42
2 x 5.79
bid
ask
+
0.10
2.14%
2 @ 07:30 PM
4.78 +0.00 (0.00%)
| Ytd | -5.35% | |
| 1y | 15.46% |
4.49
day range
4.80
3.28
52 week range
6.18
| Open | 4.62 | Prev Close | 4.68 | Low | 4.49 | High | 4.80 | Mkt Cap | 621.32M |
| Vol | 958.63K | Avg Vol | 1.32M | EPS | -0.63 | P/E | N/A | Forward P/E | 107.67 |
| Beta | 1.32 | Short Ratio | 4.50 | Inst. Own | 59.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 4.49 | 200-d Avg | 4.62 | 1yr Est | 8.40 |
| Income Statement | |||
| Total Revenue | 48.14M | ||
| Revenues (USD) | 48.14M | ||
| Cost of Revenue | 19.80M | ||
| Gross Profit | 28.34M | ||
| Operating Expenses | 39.74M | ||
| Research and Development Expense | 9.74M | ||
| Selling, General and Administrative Expense | 30.00M | ||
| Operating Income | -11.40M | ||
| Interest Expense | 281.00K | ||
| Income Tax Expense | 515.00K | ||
| Net Income | -12.16M | ||
| Net Income Common Stock | -12.16M | ||
| Net Income Common Stock (USD) | -12.16M | ||
| Consolidated Income | -12.16M | ||
| Earnings per Basic Share | -0.09 | ||
| Earnings per Basic Share (USD) | -0.09 | ||
| Earnings per Diluted Share | -0.09 | ||
| Earning Before Interest & Taxes (EBIT) | -11.36M | ||
| Earning Before Interest & Taxes (USD) | -11.36M | ||
| Weighted Average Shares | 129.46M | ||
| Weighted Average Shares Diluted | 129.46M | ||
| Balance Sheet | |||
| Cash and Equivalents | 73.85M | ||
| Cash and Equivalents (USD) | 73.85M | ||
| Investments | 188.16M | ||
| Investments Current | 188.16M | ||
| Trade and Non-Trade Receivables | 49.70M | ||
| Current Assets | 377.93M | ||
| Property, Plant & Equipment Net | 31.76M | ||
| Total Assets | 446.93M | ||
| Total Debt | 13.76M | ||
| Current Liabilities | 84.34M | ||
| Debt Non-Current | 13.76M | ||
| Total Liabilities | 124.98M | ||
| Accumulated Retained Earnings (Deficit) | -132.76M | ||
| Accumulated Other Comprehensive Income | 2.74M | ||
| Shareholders Equity | 321.95M | ||
| Shareholders Equity (USD) | 321.95M | ||
| Assets Non-Current | 69.00M | ||
| Total Debt (USD) | 13.76M | ||
| Deferred Revenue | 47.26M | ||
| Goodwill and Intangible Assets | 31.56M | ||
| Inventory | 52.25M | ||
| Liabilities Non-Current | 40.65M | ||
| Trade and Non-Trade Payables | 8.41M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 2.99M | ||
| Net Cash Flow from Financing | -814.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 8.18M | ||
| Capital Expenditure | -2.21M | ||
| Issuance (Purchase) of Equity Shares | 942.00K | ||
| Issuance (Repayment) of Debt Securities | -1.57M | ||
| Net Cash Flow from Investing | 7.02M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 9.26M | ||
| Net Cash Flow from Operations | 1.37M | ||
| Effect of Exchange Rate Changes on Cash | 606.00K | ||
| Share Based Compensation | 5.34M | ||